GlassScriptPhysician profile
Yun Woong Kim
NPI 1730404138
$3,024.91
in general payments reported to CMS, 2019-2025
27 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $88.37 · 2021: $90.84 · 2022: $187 · 2023: $891 · 2024: $1,090 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,337 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.34 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.87 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $360.34 | 2023-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $312.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $305.08 | 2022-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $304.69 | 2021-2024 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Abbvie INC. | $280.25 | 2019-2025 | |
| Amarin Pharma, INC. | $128.08 | 2019-2020 | |
| Exact Sciences Corporation | $127.10 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $123.88 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.98 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $78.88 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $70.38 | 2022-2024 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $62.04 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $58.54 | 2023-2024 | Gvoke Hypopen |
| Pfizer INC. | $56.81 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Sumitomo Pharma America, INC. | $40.25 | 2024 | Gemtesa |
| Hologic Sales and Service, LLC | $32.07 | 2025 | Aptima |
| Gilead Sciences, INC. | $21.42 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.95 | 2023 | |
| Dexcom, INC. | $17.59 | 2024 | Dexcom G6 Transmitter |
| Smith+Nephew, INC. | $17.11 | 2022 | |
| Phadia US INC. | $15.06 | 2022 | |
| Medtronic, INC. | $13.30 | 2023 | Vanta Adaptivestim |
| Shield Therapeutics INC | $13.20 | 2024 | |
| Sanofi Pasteur INC. | $12.41 | 2019 | |
| Merck Sharp & Dohme LLC | $11.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yun Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.